title: [Basic and clinical aspects of calcimimetics. Calcimimetics and vascular calcification].
abstract: Calcimimetics acted on a calcium acceptor (CaSR) as allosteric agonist and it came to be in use as a therapeutic drug of secondary hyperparathyroidism. As compared with a conventional therapeutic drug, active vitamin D, calcimimetics does not increase serum calcium and phosphorus levels, which are expected not to influence vessel calcification and cardiovascular complications. To clarify it, EVOLVE examination is going now.
authors.affiliation: The Jikei University School of Medicine, Department of Internal Medicine, Division of Nephrology and Hypertension, Japan.
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yokoyama
mesh_terms: D000818:Animals; D001808:Blood Vessels / Q000187:drug effects*; D002114:Calcinosis; D000069449:Cinacalcet; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy; D009281:Naphthalenes / Q000494:pharmacology*; D051381:Rats; D044169:Receptors, Calcium-Sensing / Q000037:antagonists & inhibitors*
chemical_list: D009281:Naphthalenes; D044169:Receptors, Calcium-Sensing; D000069449:Cinacalcet